ETA Receptor Blockade Decreases Vascular Superoxide Generation in DOCA-Salt Hypertension

Hypertension

Volumn 42, Issue 4, 2003, Pages 811-817

  Callera, Glaucia E ^a   Touyz, Rhian M ^a   Teixeira, Simone A ^a   Muscara, Marcelo N ^a   Carvalho, Maria Helena C ^a   Fortes, Zuleica B ^a   Nigro, Dorothy ^a   Schiffrin, Ernesto L ^a   Tostes, Rita C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Deoxycorticosterone; Endothelin; Hypertension, arterial; Oxidative stress; Receptors, endothelin

Indexed keywords

3 NITROTYROSINE; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ACETYLCHOLINE; ALPHA TOCOPHEROL; DEOXYCORTICOSTERONE ACETATE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; SUPEROXIDE; ZYMOSAN; 3-NITROTYROSINE; 5 (DIMETHYLAMINO) N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; 5-(DIMETHYLAMINO)-N-(3,4-DIMETHYL-5-ISOXAZOLYL)-1-NAPHTHALENESULFONAMIDE; DANSYL CHLORIDE; DEOXYCORTICOSTERONE; DRUG DERIVATIVE; ENDOTHELIN RECEPTOR; PROTEIN; SODIUM CHLORIDE; TYROSINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOVASCULAR SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; HYPERTENSION; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; OXIDATIVE STRESS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SYSTOLIC BLOOD PRESSURE; VASODILATATION; WESTERN BLOTTING; ANIMAL; AORTA; ARTERIOLE; ARTICLE; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CULTURE TECHNIQUE; DRUG ANTAGONISM; DRUG EFFECT; HISTOLOGY; IN VITRO STUDY; METABOLISM; NEUTROPHIL; PATHOPHYSIOLOGY; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; AORTA; ARTERIOLES; BLOOD PRESSURE; CULTURE TECHNIQUES; DANSYL COMPOUNDS; DESOXYCORTICOSTERONE; HYPERTENSION; MALE; NEUTROPHILS; OXIDATIVE STRESS; PROTEINS; RATS; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SODIUM CHLORIDE; SUPEROXIDES; TYROSINE; VASODILATION; VASODILATOR AGENTS;

EID: 0141997285     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.0000088363.65943.6C     Document Type: Article

References (48)

1. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001; 53: 135-159.
2. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Reports. 2000; 2: 98-105.
3. Suzuki H, Swei A, Zweifach BW, Schmid-Schonbein GW. In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats: hydroethidine microfluorography. Hypertension. 1995; 25: 1083-1089.
4. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, Malinski T. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension. 1995; 26: 854-857.
5. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996; 97: 1916-1923.
6. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q IV, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997; 80: 45-51.
7. Swei A, Lacy F, DeLano FA, Schmid-Schonbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension. 1997; 30: 1628-1633.
8. Tse WY, Maxwell SR, Thomason H, Blann A, Thorpe GH, Waite M, Holder R. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens. 1994; 89: 843-849.
9. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis and fibrosis. Hypertension. 2001; 38: 581-587.
10. Luft FC. Mechanisms and cardiovascular damage in hypertension. Hypertension. 2001; 37: 594-598.
11. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997; 95: 588-593.
12. Müller DN, Mervaala EMA, Schmidt F, Park JK, Dechend R, Genersch E, Breu B, Löffler BM, Ganten D, Schneider W, Haller, Luft FC. Effect of bosentan on NF-κB, inflammation, and tissue factor on angiotensin II-induced end-organ damage. Hypertension. 2000; 36: 282-290.
13. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension. 2001; 37: 781-786.
14. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001; 38: 1107-1111.
15. Somers MJ, Mavromatis K, Galis ZS, Harisson DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000; 101: 1722-1728.
16. Wu R, Millette E, Wu L, de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens. 2001; 19: 741-748.
17. Iglarz M, Touyz RM, Amiri F, Lavoie M-F, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003; 23: 45-51.
18. Deng LY, Schiffrin EL. Effects of endothelin on resistance arteries of DOCA-salt hypertensive rats. Am J Physiol. 1992; 262: H1782-H1787.
19. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993; 21: 294-300.
20. Li JS, Larivière R, Schiffrin EL. Effect of a non-selective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994; 24: 183-188.
21. Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, Opgenorth TJ, Takaoka M. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension. 1999; 33: 759-765.
22. Tostes RCA, David FL, Fortes ZB, Nigro D, Scivoletto R, Carvalho MHC. Deoxycorticosterone acetate-salt hypertensive rats display gender-related differences in ETB receptor-mediated vascular responses. Br J Pharmacol. 2000; 130: 1092-1098.
23. Iglarz M, Schiffrin EL. Role of endothelin-1 in hypertension. Curr Hypertens Rep. 2003; 5: 144-148.
24. Dantas APV, Tostes RCA, Fortes ZB, Costa SG, Nigro D, Carvalho MHC. In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats. Hypertension. 2002; 39: 405-411.
25. Bhalla DK, Rasmussen RE, Daniels DS. Adhesion and motility of polymorphonuclear leukocytes isolated from the blood of rats exposed to ozone: potential biomarkers of toxicity. Toxicol Appl Pharmacol. 1993; 123: 177-186.
26. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun. 2000; 269: 713-717.
27. Maczewski M, Beresewicz A. The role of endothelin, protein kinase C and free radicals in the mechanism of the post-ischemic endothelial dysfunction in guinea-pig hearts. J Mol Cell Cardiol. 2000; 32: 297-310.
28. Kahler J, Mendel S, Weckmuller J, Orzechowski HD, Mittmann C, Koster R, Paul M, Meinertz T, Munzel T. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol. 2000; 32: 1429-1437.
29. Kahler J, Ewert A, Weckmuller J, Stobbe S, Mittmann C, Koster R, Paul M, Meinertz T, Munzel T. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol. 2001; 38: 49-57.
30. Ruef J, Moser M, Kubler W, Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol. 2001; 10: 311-315.
31. Kahler J, Sill B, Koester R, Mittmann C, Orzechowski HD, Muenzel T, Meinertz T. Endothelin-1 mRNA and protein in vascular wall cells is increased by reactive oxygen species. Clin Sci (Lond). 2002; 103: 176S-178S.
32. Saito T, Itoh H, Chun T, Igaki T, Mori Y, Yamashita J, Doi K, Tanaka T, Inoue M, Masatsugu K, Fukunaga Y, Sawada N, Tojo K, Saito Y, Hosoya T, Nakao K. Oxidative stress suppresses the endothelial secretion of endothelin. J Cardiovasc Pharmacol. 1998; 31: S345-S347.
33. Saito T, Itoh H, Chun TH, Fukunaga Y, Yamashita J, Doi K, Tanaka T, Inoue M, Masatsugu K, Sawada N, Sakaguchi S, Arai H, Mukoyama M, Tojo K, Hosoya T, Nakao K. Coordinate regulation of endothelin and adrenomedullin secretion by oxidative stress in endothelial cells. Am J Physiol. 2001; 281: H1364-H1371.
34. Benov L, Sztejnberg L, Fridovich A. Critical evaluation of the use of hydroethidine as a measure of superoxide anion radical. Free Radic Biol Med. 1998; 25: 826-831.
35. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003; 107: 1053-1058.
36. Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens. 1998; 11: 921-928.
37. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension. 1998; 32: 59-64.
38. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int. 1999; 56: 1492-1498.
39. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension. 2000; 36: 142-146.
40. Newaz MA, Nawal NNA. Effect of α-tocopherol on lipid peroxidation and total antioxidant status in SHR. Am J Hypertens. 1998; 11: 1480-1485.
41. Newaz MA, Nawal NN, Rohaizan CH, Muslim N, Gapor A. α-Tocopherol increased nitric oxide synthase activity in blood vessels of SHR. Am J Hypertens. 1999; 12: 839-844.
42. Sherman DL, Keaney JF, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension. 2000; 35: 936-941.
43. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension. 2001; 38: 606-611.
44. Xu H, Fink GD, Galligan JJ. Nitric oxide-independent effects of tempol on sympathetic nerve activity and blood pressure in DOCA-salt rats. Am J Physiol. 2002; 283: H885-H892.
45. Park JB, Touyz RM, Chen X, Schiffrin EL. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2002; 15: 78-84.
46. Li JS, Turgeon A, Schiffrin EL. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Am J Hypertens. 1998; 11: 554-562.
47. Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension. 1995; 25: 769-773.
48. Park JB, Schiffrin EL. ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001; 37: 1444-1449.